"For months, many of our genomics customers have beenclamoring for Fluidigm technologies from single-cell gene expression to sampleprep for targeted resequencing. We are ready to unleash the power of Fluidigmplatforms and are anxious to offer our customers these enhanced capabilities,"said Charles Dunlop, CEO of Ambry Genetics, in a statement. "Over the pastdecade, Ambry Genetics has developed one of the best reputations in the genomicsindustry, and a big reason is our many technology platforms and our technicalabilities to apply them. Having the Fluidigm technology in house is a majorstep forward for us, and will continue to solidify Ambry's reputation as aleader in this space."
"Ambry Genetics has a first-class reputation as an adopterof leading technologies," added Gajus Worthington, president and CEO ofFluidigm. "We at Fluidigm are thrilled that our products will be part ofAmbry's portfolio of services, and we are excited about the prospect of workingclosely together. With the combined expertise, customer focus, andtechnological prowess of Fluidigm and Ambry, we are confident we will deliver anew level of value to Ambry's customers."
